Revisiting the Magic Pill of 2024
Updated
The problem with stocks that have large potential runways is that you never know when to begin riding it to milk the maximum profits of the trade..
for Natco to deliver in 2024 it has three problems and by early February of 2024 we should get past all of them...
the API plant in Manali, Chennai should be able to restart operations,
the final USFDA conclusion on the observations of Kothur plant will be known and
the expected lower profits in Q3 would have been announced ..
Then it will be all set for the higher quantity play for gRevlimid manufacturing profit in Q4 and 2 quarters of booking the gRevlimid sale profit share in Q1 & Q2...
Follow this with a victory for an old para iv filing or an acquisition later in the year and it will make all the right noises for a PE rerating
for Natco to deliver in 2024 it has three problems and by early February of 2024 we should get past all of them...
the API plant in Manali, Chennai should be able to restart operations,
the final USFDA conclusion on the observations of Kothur plant will be known and
the expected lower profits in Q3 would have been announced ..
Then it will be all set for the higher quantity play for gRevlimid manufacturing profit in Q4 and 2 quarters of booking the gRevlimid sale profit share in Q1 & Q2...
Follow this with a victory for an old para iv filing or an acquisition later in the year and it will make all the right noises for a PE rerating
Note
we all saw 1100 getting breached and now going through a correction... while the ATH has not happened as yet it did make 52 week high... for some reason due to the price volume behaviour on reaching 52WH its been put in the ASM framework.... Expectations have become more pronounced.. USFDA classification on Kothur plant is the only key monitorable remaining and that can come any day now
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.